1
|
Das S, Samajdar SS, Mukherjee S, Sarkar S, Sen S, Pathak A, Lundborg CS, Selvarajan S, Tripathi SK, Pal J, Chatterjee N, Joshi SR. Ten clinical pharmacological interventions in routine care to ensure better treatment outcomes. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2023:7146135. [PMID: 37105526 DOI: 10.1093/ijpp/riad032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- Saibal Das
- Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| | - Shambo Samrat Samajdar
- Department of Clinical and Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata, India
| | - Shatavisa Mukherjee
- Department of Clinical and Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata, India
| | - Sougata Sarkar
- Department of Clinical and Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata, India
| | - Sumalya Sen
- Department of Clinical and Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata, India
| | - Ashish Pathak
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
- Department of Pediatrics, RD Gardi Medical College, Ujjain, India
| | | | - Sandhiya Selvarajan
- Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
| | | | - Jyotirmoy Pal
- Department of Medicine, RG Kar College and Hospital, Kolkata, India
| | - Nandini Chatterjee
- Department of Medicine, Institute of Postgraduate Medical Education and Research and SSKM Hospital, Kolkata, India
| | | |
Collapse
|
2
|
Belančić A, Sans-Pola C, Jouanjus E, Alcubilla P, Arellano AL, Žunić M, Nogueiras-Álvarez R, Roncato R, Sáez-Peñataro J. European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology. Eur J Clin Pharmacol 2022; 78:691-694. [PMID: 35037981 PMCID: PMC8761867 DOI: 10.1007/s00228-022-03277-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 01/10/2022] [Indexed: 11/28/2022]
Abstract
The European Association for Clinical Pharmacology and Therapeutics (EACPT) is a leading society in Europe serving the European and global Clinical Pharmacology and Therapeutics community. Its specific aims include promotion of the utilisation and divulgation of the utility of clinical pharmacology services in health care delivery. EACPT currently has four active working groups (WGs): Education, Regulatory affairs, Clinical research and Young Clinical Pharmacologists (YCP WG). EACPT YCP WG was established in 2015 with the idea of improving education, research, training and networking/mobility opportunities for YCPs across Europe and globe. The main objective of the present manuscript is to provide detailed information on general characteristics, structure, chronogram, objectives, accomplishments and current/future focus areas of the EACPT YCP WG. Consequently, we tend to notably enhance EACPT YCP WG's visibility, increase the number of its members and mobility/networking options and to expand areas of activity even more. Moreover, by this we can also make clinical pharmacology more attractive to early career fellows and colleagues and empower its position alongside other medical specialties.
Collapse
Affiliation(s)
- Andrej Belančić
- Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000, Rijeka, Croatia.
| | - Carla Sans-Pola
- Department of Clinical Pharmacology, Vall d'Hebron Hospital Universitari, Barcelona, Spain
| | - Emilie Jouanjus
- Addictovigilance Center, Department of Medical Pharmacology, Toulouse University Hospital, Toulouse, France
| | - Pau Alcubilla
- Department of Clinical Pharmacology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Ana Lucía Arellano
- Department of Clinical Pharmacology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Miodrag Žunić
- Department of Anesthesiology, Intensive Care and Pain Management, University Medical Center Maribor, Maribor, Slovenia
| | - Rita Nogueiras-Álvarez
- Department of Clinical Pharmacology, Badajoz University Hospital, Badajoz, Extremadura, Spain
| | - Rossana Roncato
- Experimental and Clinical Pharmacology Unit, Centro Di Riferimento Oncologico Di Aviano (CRO) IRCCS, Aviano, Italy
- Italian Society of Pharmacology (SIF), Milan, Italy
| | | |
Collapse
|
3
|
Spanakis M, Patelarou AE, Patelarou E. Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice. J Pers Med 2020; 10:E56. [PMID: 32610469 PMCID: PMC7565499 DOI: 10.3390/jpm10030056] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 06/24/2020] [Accepted: 06/26/2020] [Indexed: 12/27/2022] Open
Abstract
Personalized, stratified, or precision medicine (PM) introduces a new era in healthcare that tries to identify and predict optimum treatment outcomes for a patient or a cohort. It also introduces new scientific terminologies regarding therapeutic approaches and the need of their adoption from healthcare providers. Till today, evidence-based practice (EBP) was focusing on population averages and their variances among cohorts for clinical values that are essential for optimizing healthcare outcome. It can be stated that EBP and PM are complementary approaches for a modern healthcare system. Healthcare providers through EBP often see the forest (population averages) but miss the trees (individual patients), whereas utilization of PM may not see the forest for the trees. Nursing personnel (NP) play an important role in modern healthcare since they are consulting, educating, and providing care to patients whose needs often needs to be individualized (personalized nursing care, PNC). Based on the clinical issues earlier addressed from clinical pharmacology, EBP, and now encompassed in PM, this review tries to describe the challenges that NP have to face in order to meet the requisites of the new era in healthcare. It presents the demands that should be met for upgrading the provided education and expertise of NP toward an updated role in a modern healthcare system.
Collapse
Affiliation(s)
- Marios Spanakis
- Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology—Hellas (FORTH), Heraklion, GR-70013 Crete, Greece
- Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Heraklion, GR-71004 Crete, Greece; (A.E.P.); (E.P.)
| | - Athina E. Patelarou
- Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Heraklion, GR-71004 Crete, Greece; (A.E.P.); (E.P.)
| | - Evridiki Patelarou
- Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Heraklion, GR-71004 Crete, Greece; (A.E.P.); (E.P.)
| |
Collapse
|
4
|
Gulmez SE, Aydin V, Akici A. Footprints of Clinical Pharmacology in Turkey: Past, Present, and Future. Clin Ther 2020; 42:351-362. [PMID: 31955969 DOI: 10.1016/j.clinthera.2019.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 11/21/2019] [Accepted: 12/23/2019] [Indexed: 10/25/2022]
Abstract
Clinical pharmacology is an interdisciplinary field that encompasses all components of the relationship between drugs and humans. All clinical pharmacology professionals aim to support an improved quality of drug-oriented health services by providing teaching, research, and routine health care services that ensure more tolerable and more effective, suitable, and cost-effective use of drugs. Subsections of clinical pharmacology include clinical trials, pharmacoepidemiology and drug use, pharmacovigilance, pharmacoeconomics, the rational use of medicines, pharmacotherapy consultation, drug monitoring, counseling to authorities and industry, pharmacogenetics, and other practices. By approaching these subsections as part of 3 main aspects of clinical pharmacology-education, research, and health care-this review aims to provide local and international practitioners with detailed information about clinical pharmacology practices in Turkey and to contribute to building the network of communication and collaboration. This review also aims to play an encouraging and pioneering role for Turkey's national community and other countries that have not yet made clinical pharmacology functional in improving the quality of health services, promoting the dissemination of rational use of medicines, helping the set-up of clinical pharmacology organizations, enhancing quantity and quality of the clinical pharmacology workforce, and increasing the infrastructural facilities.
Collapse
Affiliation(s)
- Sinem Ezgi Gulmez
- Department of Medical Pharmacology, School of Medicine, Koç University, Istanbul, Turkey.
| | - Volkan Aydin
- Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey
| | - Ahmet Akici
- Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey
| |
Collapse
|
5
|
Groeneveld GJ, Martin JH. Parasitic pharmacology: A plausible mechanism of action for cannabidiol. Br J Clin Pharmacol 2019; 86:189-191. [PMID: 31290177 PMCID: PMC7015737 DOI: 10.1111/bcp.14028] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 05/13/2019] [Accepted: 06/03/2019] [Indexed: 12/21/2022] Open
Affiliation(s)
- Geert Jan Groeneveld
- Centre for Human Drug Research, Leiden, The Netherlands.,Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jennifer H Martin
- The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), New Lambton Heights, Australia.,Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
| |
Collapse
|
6
|
Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review. Eur J Clin Pharmacol 2018; 74:1663-1670. [PMID: 30008120 DOI: 10.1007/s00228-018-2511-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Accepted: 06/22/2018] [Indexed: 10/28/2022]
|
7
|
Day RO, Snowden L, McLachlan AJ. Life‐threatening drug interactions: what the physician needs to know. Intern Med J 2017; 47:501-512. [DOI: 10.1111/imj.13404] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2016] [Revised: 11/11/2016] [Accepted: 11/11/2016] [Indexed: 02/06/2023]
Affiliation(s)
- Richard O. Day
- Department of Clinical Pharmacology and Toxicology St Vincent's Hospital Sydney New South Wales Australia
- School of Medical Sciences, Medicine University of New South Wales Sydney New South Wales Australia
- St Vincent's Clinical School, Medicine University of New South Wales Sydney New South Wales Australia
| | - Leone Snowden
- New South Wales Medicines Information Centre Sydney New South Wales Australia
| | - Andrew J. McLachlan
- Faculty of Pharmacy University of Sydney and Centre for Education and Research on Ageing, Concord Hospital Sydney New South Wales Australia
| |
Collapse
|
8
|
Modelling Medications for Public Health Research. Online J Public Health Inform 2017; 8:e190. [PMID: 28149446 PMCID: PMC5266755 DOI: 10.5210/ojphi.v8i2.6809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Most patients with chronic disease are prescribed multiple medications, which are recorded in
their personal health records. This is rich information for clinical public health researchers but
also a challenge to analyse. This paper describes the method that was undertaken within the Public
Health Research Data Management System (PHReDMS) to map medication data retrieved from individual
patient health records for population health researcher’s use. The PHReDMS manages clinical,
health service, community and survey research data within a secure web environment that allows for
data sharing amongst researchers. The PHReDMS is currently used by researchers to answer a broad
range of questions, including monitoring of prescription patterns in different population groups and
geographic areas with high incidence/prevalence of chronic renal, cardiovascular, metabolic and
mental health issues. In this paper, we present the general notion of abstraction network, a higher
level network that sits above a terminology and offers compact and more easily understandable view
of its content. We demonstrate the utilisation of abstraction network methodology to examine
medication data from electronic medical records to allow a compact and more easily understandable
view of its content.
Collapse
|
9
|
Maroñas O, Latorre A, Dopazo J, Pirmohamed M, Rodríguez-Antona C, Siest G, Carracedo Á, LLerena A. Progress in pharmacogenetics: consortiums and new strategies. Drug Metab Pers Ther 2016; 31:17-23. [PMID: 26913460 DOI: 10.1515/dmpt-2015-0039] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 01/25/2016] [Indexed: 11/15/2022]
Abstract
Pharmacogenetics (PGx), as a field dedicated to achieving the goal of personalized medicine (PM), is devoted to the study of genes involved in inter-individual response to drugs. Due to its nature, PGx requires access to large samples; therefore, in order to progress, the formation of collaborative consortia seems to be crucial. Some examples of this collective effort are the European Society of Pharmacogenomics and personalized Therapy and the Ibero-American network of Pharmacogenetics. As an emerging field, one of the major challenges that PGx faces is translating their discoveries from research bench to bedside. The development of genomic high-throughput technologies is generating a revolution and offers the possibility of producing vast amounts of genome-wide single nucleotide polymorphisms for each patient. Moreover, there is a need of identifying and replicating associations of new biomarkers, and, in addition, a greater effort must be invested in developing regulatory organizations to accomplish a correct standardization. In this review, we outline the current progress in PGx using examples to highlight both the importance of polymorphisms and the research strategies for their detection. These concepts need to be applied together with a proper dissemination of knowledge to improve clinician and patient understanding, in a multidisciplinary team-based approach.
Collapse
|
10
|
Auffray C, Caulfield T, Griffin JL, Khoury MJ, Lupski JR, Schwab M. From genomic medicine to precision medicine: highlights of 2015. Genome Med 2016; 8:12. [PMID: 26825779 PMCID: PMC4733269 DOI: 10.1186/s13073-016-0265-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Affiliation(s)
- Charles Auffray
- European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Université de Lyon, 69007, Lyon, France.
| | - Timothy Caulfield
- Faculty of Law and School of Public Health, Health Law Institute, University of Alberta, Alberta, T6G 2HS, Canada.
| | - Julian L Griffin
- Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, UK. .,Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn Road, Cambridge, CB1 9NL, UK.
| | - Muin J Khoury
- Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
| | - James R Lupski
- Department of Molecular and Human Genetics, Department of Pediatrics, and Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza Room 604B, Houston, 77030, TX, USA. .,Texas Children's Hospital, Houston, 77030, TX, USA.
| | - Matthias Schwab
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 70376, Stuttgart, Germany. .,Department of Clinical Pharmacology, University Hospital, 72076, Tübingen, Germany. .,Department of Pharmacy and Biochemistry, University of Tübingen, 72076, Tübingen, Germany.
| |
Collapse
|
11
|
Aronson JK. How a VOICE for clinical pharmacology turns into a RECIPE for its development. Transl Clin Pharmacol 2016. [DOI: 10.12793/tcp.2016.24.1.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Jeffrey K Aronson
- Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Woodstock Road, Oxford OX2 6GG, UK
| |
Collapse
|
12
|
Martin JH, Henry D, Gray J, Day R, Bochner F, Ferro A, Pirmohamed M, Mörike K, Schwab M. Achieving the World Health Organization's vision for clinical pharmacology. Br J Clin Pharmacol 2015; 81:223-7. [PMID: 26466826 DOI: 10.1111/bcp.12803] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Revised: 10/08/2015] [Accepted: 10/12/2015] [Indexed: 01/11/2023] Open
Abstract
Clinical pharmacology is a medical specialty whose practitioners teach, undertake research, frame policy, give information and advice about the actions and proper uses of medicines in humans and implement that knowledge in clinical practice. It involves a combination of several activities: drug discovery and development, training safe prescribers, providing objective and evidence-based therapeutic information to ethics, regulatory and pricing bodies, supporting patient care in an increasingly subspecialized arena where co-morbidities, polypharmacy, altered pharmacokinetics and drug interactions are common and developing and contributing to medicines policies for Governments. Clinical pharmacologists must advocate drug quality and they must also advocate for sustainability of the Discipline. However for this they need appropriate clinical service and training support. This Commentary discusses strategies to ensure the Discipline is supported by teaching, training and policy organizations, to communicate the full benefits of clinical pharmacology services, put a monetary value on clinical pharmacology services and to grow the clinical pharmacology workforce to support a growing clinical, academic and regulatory need.
Collapse
Affiliation(s)
- Jennifer H Martin
- Discipline of Clinical Pharmacology, University of Newcastle, Australia.,Department Clinical Pharmacology, University Hospital Tübingen, Germany
| | - David Henry
- Institute for Clinical Evaluative Sciences and University of Toronto, Toronto
| | - Jean Gray
- Dalhousie University Faculty of Medicine, Halifax, Canada
| | - Richard Day
- Clinical Pharmacology, St Vincent's Hospital Clinical School and Pharmacology, School of Medical Sciences, Faculty of Medicine, UNSW, Sydney
| | - Felix Bochner
- The University of Adelaide, Royal Adelaide Hospital, South Australia, Australia
| | - Albert Ferro
- Department of Clinical Pharmacology, Kings College London
| | - Munir Pirmohamed
- The Wolfson Centre for Personalized Medicine, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom
| | - Klaus Mörike
- Department Clinical Pharmacology, University Hospital Tübingen, Germany
| | - Matthias Schwab
- Department Clinical Pharmacology, University Hospital Tübingen, Germany.,Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
| |
Collapse
|